ABSTRACT
One possible determinant of COVID-19 severity is immune imprinting (IP) by Common Cold Coronavirus (CCCV). As IP occurs only in recall immune responses, we investigated the immune response to SARS-CoV-2 in a cohort of unvaccinated individual to determine whether their immune response aligned with the primary or recall immune response patterns.
Analysis of the Ig isotype response trajectories to the Mpro, NP, and S structural proteins and the S RBD in this group of 191 patients and 44 controls revealed a pattern of recall response in 94.2 % of cases. The levels of antibodies correlated positively with the severity of the condition rather than a milder course. High-resolution flow cytometry of fresh PBMNCs showed trajectories of plasmablasts, B cell subsets, and cTfh, suggesting a recall response. The transcriptomic profile demonstrated that this group was directly comparable to other contemporary cohorts. Overall, these findings support the idea that the response to SARS-CoV-2 is, in most cases, a recall response, likely due to B and T memory cells to CCCV, and therefore susceptible to immune imprinting and antibody-dependent enhancement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Instituto de Salud Carlos III, Madrid, Spain, grants COV20/00416, Cov20/00654, and COV20/00388 to RP-B, AT-S, and JB-M respectively, and co-financed by the European Regional Development Fund (ERDF). D.A-S is the recipient of a doctoral fellowship from the Vall Hebron Research Institute, Barcelona, Spain (up to 2022 and a postdoctoral fellowship Sara Borrell, CD23/00114 (from 2024). A.S-M was supported by a postdoctoral grant, Juan Rodes (JR18/00022), from Instituto de Salud Carlos III through the Ministry of Economy and Competitiveness, Spain. A.S.P was financially supported by the Spanish Ministerio de Ciencia e Innovacion, grant PID2019-104830RB-I00, and by the Departament Economia i Coneixement de la Generalitat de Catalunya, grant 2017SGR622 (GRBIO). Bioinformatics analysis has been conducted in the Statistics and Bioinformatics Unit (UEB) at Vall Hebron Research Institute (VHIR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional ethics board approved this project of the three institutions (HUVH: Protocol number PR(AG)242/2020, HUGTP, and HUB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors declare that they have no conflicts of interest.
DATA AVAILABILITY
Supplemental tables contain the additional data required to re-analyze the data: the xlsx file with the transcriptomic data will be made available on request.
